MEI Pharma, Inc. is an oncology company. The Company is focused on the clinical development of drugs and therapies for treatment of cancer. The Company's portfolio of clinical drug candidates includes Pracinostat, ME-344 and PWT143. Pracinostat is an orally available histone deacetylase (HDAC) inhibitor indicated for the treatment of advanced hematologic diseases, such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). ME-344 is an isoflavone-based mitochondrial inhibitor targeting a mitochondrial component of the terminal respiratory chain complex in rapidly proliferating cells. PWT143 is an oral inhibitor of phosphatidylinositide 3-kinase (PI3K) delta, a molecular target that plays a critical role in the proliferation and survival of hematologic cancer cells. Pracinostat has been tested in multiple Phase I and Phase II clinical trials in advanced hematologic malignancies and solid tumor indications.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Drug Manufacturers - Other
- Sub-Industry: N/A
- Symbol: NASDAQ:MEIP
- CUSIP: N/A
- Web: www.meipharma.com
- Market Cap: $77.96 million
- Outstanding Shares: 36,772,000
- 50 Day Moving Avg: $1.62
- 200 Day Moving Avg: $1.59
- 52 Week Range: $1.23 - $2.28
Sales & Book Value:
- Trailing P/E Ratio: 62.35
- Foreward P/E Ratio: -1.53
- P/E Growth: -985.00
- Annual Revenue: $22.8 million
- Price / Sales: 3.42
- Book Value: $1.49 per share
- Price / Book: 1.42
- EBIDTA: $1.06 million
- Return on Equity: -7.59%
- Return on Assets: -6.49%
- Current Ratio: 17.42%
- Quick Ratio: 17.42%
- Average Volume: 161,330 shs.
- Beta: 1.01
- Short Ratio: 0.38
Frequently Asked Questions for MEI Pharma (NASDAQ:MEIP)
What is MEI Pharma's stock symbol?
MEI Pharma trades on the NASDAQ under the ticker symbol "MEIP."
How were MEI Pharma's earnings last quarter?
MEI Pharma Inc (NASDAQ:MEIP) announced its quarterly earnings results on Thursday, May, 4th. The company reported ($0.02) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.03) by $0.01. The company had revenue of $4.51 million for the quarter, compared to the consensus estimate of $5 million. View MEI Pharma's Earnings History.
Where is MEI Pharma's stock going? Where will MEI Pharma's stock price be in 2017?
3 equities research analysts have issued 1 year target prices for MEI Pharma's stock. Their forecasts range from $2.00 to $6.50. On average, they anticipate MEI Pharma's share price to reach $4.25 in the next twelve months. View Analyst Ratings for MEI Pharma.
Who are some of MEI Pharma's key competitors?
Who owns MEI Pharma stock?
MEI Pharma's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (4.25%), Vanguard Group Inc. (1.79%), FMR LLC (0.95%), Geode Capital Management LLC (0.38%), Oxford Asset Management (0.30%) and Goldman Sachs Group Inc. (0.22%). View Institutional Ownership Trends for MEI Pharma.
Who bought MEI Pharma stock? Who is buying MEI Pharma stock?
MEI Pharma's stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Oxford Asset Management, Goldman Sachs Group Inc., Vanguard Group Inc., TFS Capital LLC, FMR LLC and Geode Capital Management LLC. View Insider Buying and Selling for MEI Pharma.
How do I buy MEI Pharma stock?
Shares of MEI Pharma can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of MEI Pharma stock cost?
One share of MEI Pharma stock can currently be purchased for approximately $2.12.
Earnings History for MEI Pharma (NASDAQ:MEIP)Earnings History by Quarter for MEI Pharma (NASDAQ:MEIP)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|5/4/2017||Q3 2017||($0.03)||($0.02)||$5.00 million||$4.51 million||View||N/A|
|2/8/2017||Q217||($0.29)||$0.32||$1.25 million||$17.20 million||View||N/A|
|11/8/2016||Q1 2017||($0.14)||($0.12)||$0.63 million||$1.10 million||View||N/A|
Earnings Estimates for MEI Pharma (NASDAQ:MEIP)
Current Year EPS Consensus Estimate: $0.02 EPS
Next Year EPS Consensus Estimate: $-1.39 EPS
Dividend History for MEI Pharma (NASDAQ:MEIP)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for MEI Pharma (NASDAQ:MEIP)
Insider Ownership Percentage: 4.62%Insider Trades by Quarter for MEI Pharma (NASDAQ:MEIP)
Institutional Ownership Percentage: 15.01%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|11/9/2015||Vivo Ventures Vii, Llc||Major Shareholder||Sell||390,572||$1.84||$718,652.48|| |
|1/21/2015||Charles V Baltic III||Director||Buy||5,000||$3.81||$19,050.00|| |
|12/9/2014||Leaf Ventures Ii L.P. New||Major Shareholder||Sell||79,085||$6.01||$475,300.85|| |
|12/8/2014||Leaf Ventures Ii L.P. New||Major Shareholder||Sell||9,004||$6.05||$54,474.20|| |
|6/30/2014||Charles V Baltic III||Director||Buy||2,000||$6.56||$13,120.00|| |
|10/29/2013||Vivo Ventures Vii, Llc||Major Shareholder||Sell||299,609||$8.21||$2,459,789.89|| |
|10/2/2013||Vivo Ventures Vii, Llc||Major Shareholder||Sell||581,646||$10.16||$5,909,523.36|| |
|8/16/2013||Charles V Baltic III||Director||Buy||2,600||$6.82||$17,732.00|| |
|6/28/2013||Vivo Ventures Vii, Llc||Major Shareholder||Sell||7,337||$7.58||$55,614.46|| |
|6/11/2013||Vivo Ventures V, Llc||Major Shareholder||Sell||13,727||$7.80||$107,070.60|| |
|5/16/2013||Vivo Ventures Vii, Llc||Major Shareholder||Sell||17,428||$9.07||$158,071.96|| |
|5/8/2013||Leaf Ventures Ii L.P. New||Major Shareholder||Sell||200,000||$8.58||$1,716,000.00|| |
|1/25/2013||Charles V Baltic III||Director||Buy||10,200||$6.04||$61,608.00|| |
|12/21/2012||Charles V Baltic III||Director||Buy||3,500||$7.18||$25,130.00|| |
Headline Trends for MEI Pharma (NASDAQ:MEIP)
Latest Headlines for MEI Pharma (NASDAQ:MEIP)
MEI Pharma (MEIP) Chart for Saturday, May, 27, 2017